• Member Login
• Sitemap
• Contact
• RSS feed

Peira shows neuroscience and oncology research tools on the Belgian Pavilion at Bio 2011 in Washington, US (28-30 June 2011)

20/06/2011

Peira is one of the companies that participates in the Belgian Economic Mission to the US and puts two new developments, designed in Flanders-Belgium, on display at the Bio 2011 International Convention. The Bio Convention is one of the largest events for companies and research organisations active in life sciences/biotechnoloy. The Belgian booth will host more than 60 Belgian companies active in the field. The Flemish representation at the convention is organised by FlandersBio, the cluster organisation for the biotech sector in Flanders, and FIT. This year the Pavilion will be inaugurated by H.R.H. Prince Philippe on Tuesday 28 June 2011.

Peira will give a live demonstration of an application for Neuroscience research and of a research tool for oncology during the convention on the Belgian booth (booth number 4823).

• “Peira SliceTilter 2.0” is a second generation research tool developed in cooperation with imec. The new instrument will allow to capture real time data from hippocampal brainslices which are cultured in the incubator. The new tool ensures optimal growth of brain slices on electronic chips for more than a month. It enables in-vitro investigation of long-term processes in brain circuits.
• “Peira TM900” is a handheld tumor measurement device used to measure subcutaneous tumors in immuno deficient mice. Peira, in partnership with ThromboGenics, obtained a grant from the governmental Agency for Innovation by Science and Technology (IWT) to study the feasibility of developing a handheld device that would enhance in vivo research experiments in oncology and eliminate bias from manual procedures. Peira is now looking for European lead users who are interested to participate in the Bèta testing program as of October 2011.

Besides Peira the following Flemish companies and organisations will be represented on the Belgian Pavilion: ActoGeniX, Amakem, Bio Base Europe, Bio-Plus services, Cartagenia, De Clercq & Partners, e-novex, FluidDa, Galapagos, Genae, Genzyme, imec, Janssen Pharmaceutica, LifeTechLimburg, Nateco, reMYND, Shire-Movetis nv, TiGeniX, TTO Flanders (UGent, K.U.Leuven, Hasselt University, University of Antwerp, Vrije Universiteit Brussel), University of Antwerp - Vaxinfectio, VIB, VITO and Vivaldi Software.

About imec

Imec performs world-leading research in nanoelectronics. Imec leverages its scientific knowledge with the innovative power of its global partnerships in ICT, healthcare and energy. Imec delivers industry-relevant technology solutions. In a unique high-tech environment, its international top talent is committed to providing the building blocks for a better life in a sustainable society. Imec is headquartered in Leuven, Belgium, and has offices in Belgium, the Netherlands, Taiwan, US, China and Japan. Its staff of about 1,900 people includes more than 500 industrial residents and guest researchers. In 2010, imec's revenue (P&L) was 285 million euro. Further information on imec can be found at www.imec.be.

Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a "stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shanghai) Co. Ltd.).

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead product ocriplasmin (microplasmin) has completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). Ocriplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent

International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR.

Source: Peira